Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel

Seino,Manabu; Okada,Masashi; Sakaki,Hirotsugu; Takeda,Hiroyuki; Watarai,Hikaru; Suzuki,Shuhei; Seino,Shizuka; Kuramoto,Kenta; Ohta,Tsuyoshi; Nagase,Satoru; Kurachi,Hirohisa; Kitanaka,Chifumi

doi:10.3892/or.2015.4377

Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel

Authors:
- Manabu Seino
- Masashi Okada
- Hirotsugu Sakaki
- Hiroyuki Takeda
- Hikaru Watarai
- Shuhei Suzuki
- Shizuka Seino
- Kenta Kuramoto
- Tsuyoshi Ohta
- Satoru Nagase
- Hirohisa Kurachi
- Chifumi Kitanaka
View Affiliations

Affiliations: Department of Molecular Cancer Science, Yamagata University School of Medicine, Yamagata 990‑9585, Japan, Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata 990‑9585, Japan
Published online on: November 2, 2015 https://doi.org/10.3892/or.2015.4377
Pages: 593-601

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most lethal gynecological malignancy, for which platinum- and taxane-based chemotherapy plays a major role. Chemoresistance of ovarian cancer poses a major obstacle to the successful management of this devastating disease; however, effective measures to overcome platinum and taxane resistance are yet to be established. In the present study, while investigating the mechanism underlying the chemoresistance of ovarian cancer, we found that JNK may have a key role in the resistance of ovarian cancer cells to cisplatin and paclitaxel. Importantly, whereas simultaneous application of a JNK inhibitor and either of the chemotherapeutic agents had contrasting effects for cisplatin (enhanced cytotoxicity) and paclitaxel (decreased cytotoxicity), JNK inhibitor treatment prior to chemotherapeutic agent application invariably enhanced the cytotoxicity of both drugs, suggesting that the basal JNK activity is commonly involved in the chemoresistance of ovarian cancer cells to cisplatin and paclitaxel in contrast to drug‑induced JNK activity which may have different roles for these two drugs. Furthermore, we confirmed using non-transformed human and rodent fibroblasts that sequential application of the JNK inhibitor and the chemotherapeutic agents did not augment their toxicity. Thus, our findings highlight for the first time the possible differential roles of the basal and induced JNK activities in the chemoresistance of ovarian cancer cells and also suggest that time‑staggered JNK inhibition may be a rational and promising strategy to overcome the resistance of ovarian cancer to platinum- and taxane-based chemotherapy.

View Figures

View References

1	Jayson GC, Kohn EC, Kitchener HC and Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014. View Article : Google Scholar : PubMed/NCBI
2	Bookman MA: The addition of new drugs to standard therapy in the first-line treatment of ovarian cancer. Ann Oncol. 21(Suppl 7): vii211–vii217. 2010. View Article : Google Scholar : PubMed/NCBI
3	Liu X, Gao Y, Lu Y, Zhang J, Li L and Yin F: Oncogenes associated with drug resistance in ovarian cancer. J Cancer Res Clin Oncol. 141:381–395. 2015. View Article : Google Scholar
4	Yin F, Liu X, Li D, Wang Q, Zhang W and Li L: Tumor suppressor genes associated with drug resistance in ovarian cancer (Review). Oncol Rep. 30:3–10. 2013.PubMed/NCBI
5	Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC and Ozols RF: Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol. 34:2583–2586. 1985. View Article : Google Scholar : PubMed/NCBI
6	Yu D, Wolf JK, Scanlon M, Price JE and Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res. 53:891–898. 1993.PubMed/NCBI
7	Suzuki N, Aoki D, Tamada Y, Susumu N, Orikawa K, Tsukazaki K, Sakayori M, Suzuki A, Fukuchi T, Mukai M, et al: HMOCC-1, a human monoclonal antibody that inhibits adhesion of ovarian cancer cells to human mesothelial cells. Gynecol Oncol. 95:290–298. 2004. View Article : Google Scholar : PubMed/NCBI
8	Liu Z, Yamanouchi K, Ohtao T, Matsumura S, Seino M, Shridhar V, Takahashi T, Takahashi K and Kurachi H: High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer. Anticancer Res. 34:2331–2340. 2014.PubMed/NCBI
9	Yamanouchi K, Ohta T, Liu Z, Oji Y, Sugiyama H, Shridhar V, Matsumura S, Takahashi T, Takahashi K and Kurachi H: The Wilms' tumor gene WT1 - 17AA/- KTS splice variant increases tumorigenic activity through up-regulation of vascular endo-thelial growth factor in an in vivo ovarian cancer model. Transl Oncol. 7:580–589. 2014. View Article : Google Scholar : PubMed/NCBI
10	Ohta T, Ohmichi M, Shibuya T, Takahashi T, Tsutsumi S, Takahashi K and Kurachi H: Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer Biol Ther. 13:408–416. 2012. View Article : Google Scholar : PubMed/NCBI
11	Seino M, Okada M, Shibuya K, Seino S, Suzuki S, Ohta T, Kurachi H and Kitanaka C: Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. Anticancer Res. 34:4723–4731. 2014.PubMed/NCBI
12	Suzuki S, Okada M, Shibuya K, Seino M, Sato A, Takeda H, Seino S, Yoshioka T and Kitanaka C: JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget. 6:458–470. 2015. View Article : Google Scholar :
13	Kiguchi K, Kubota T, Aoki D, Udagawa Y, Yamanouchi S, Saga M, Amemiya A, Sun FX, Nozawa S, Moossa AR, et al: A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis. 16:751–756. 1998. View Article : Google Scholar
14	Okada M, Shibuya K, Sato A, Seino S, Suzuki S, Seino M and Kitanaka C: Targeting the K-Ras-JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. Oncotarget. 5:5100–5112. 2014. View Article : Google Scholar : PubMed/NCBI
15	Okada M, Sato A, Shibuya K, Watanabe E, Seino S, Suzuki S, Seino M, Narita Y, Shibui S, Kayama T, et al: JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression. Int J Oncol. 44:591–599. 2014.
16	Wang X, Song H, Yu Q, Liu Q, Wang L, Liu Z and Yu Z: Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncol Rep. 33:526–532. 2015.
17	Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D and Murata Y: Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 274:31648–31654. 1999. View Article : Google Scholar : PubMed/NCBI
18	Bogoyevitch MA and Arthur PG: Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim Biophys Acta. 1784:76–93. 2008. View Article : Google Scholar
19	Kolomeichuk SN, Terrano DT, Lyle CS, Sabapathy K and Chambers TC: Distinct signaling pathways of microtubule inhibitors - vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J. 275:1889–1899. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lee LF, Li G, Templeton DJ and Ting JP: Paclitaxel (Taxol)- induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK). J Biol Chem. 273:28253–28260. 1998. View Article : Google Scholar : PubMed/NCBI
21	Selimovic D, Hassan M, Haikel Y and Hengge UR: Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cell Signal. 20:311–322. 2008. View Article : Google Scholar
22	Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, Cook SJ, Burgering BM, Coombes RC and Lam EW: Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res. 66:212–220. 2006. View Article : Google Scholar : PubMed/NCBI
23	Wang TH, Popp DM, Wang HS, Saitoh M, Mural JG, Henley DC, Ichijo H and Wimalasena J: Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells. J Biol Chem. 274:8208–8216. 1999. View Article : Google Scholar : PubMed/NCBI
24	Abend M: Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol. 79:927–941. 2003. View Article : Google Scholar
25	Stordal B and Davey R: A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: Role of BRCA1. Curr Cancer Drug Targets. 9:354–365. 2009. View Article : Google Scholar : PubMed/NCBI
26	Stordal B, Pavlakis N and Davey R: A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. Cancer Treat Rev. 33:688–703. 2007. View Article : Google Scholar : PubMed/NCBI
27	Eckhoff K, Flurschütz R, Trillsch F, Mahner S, Jänicke F and Milde-Langosch K: The prognostic significance of Jun transcription factors in ovarian cancer. J Cancer Res Clin Oncol. 139:1673–1680. 2013. View Article : Google Scholar : PubMed/NCBI
28	Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, et al: c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 16:184–194. 2010. View Article : Google Scholar
29	Hayakawa J, Depatie C, Ohmichi M and Mercola D: The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem. 278:20582–20592. 2003. View Article : Google Scholar : PubMed/NCBI
30	Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C, Ohmichi M, McClelland M and Mercola D: Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell. 16:521–535. 2004. View Article : Google Scholar : PubMed/NCBI
31	Li QQ, Lee RX, Liang H, Wang G, Li JM, Zhong Y and Reed E: β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK. Int J Oncol. 43:721–728. 2013.PubMed/NCBI
32	Ohmichi M, Hayakawa J, Tasaka K, Kurachi H and Murata Y: Mechanisms of platinum drug resistance. Trends Pharmacol Sci. 26:113–116. 2005. View Article : Google Scholar : PubMed/NCBI
33	Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R and Mercola D: The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem. 272:14041–14044. 1997. View Article : Google Scholar : PubMed/NCBI
34	Parekh H and Simpkins H: Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells. Cancer Chemother Pharmacol. 37:457–462. 1996. View Article : Google Scholar : PubMed/NCBI
35	Stordal B, Hamon M, McEneaney V, Roche S, Gillet JP, O'Leary JJ, Gottesman M and Clynes M: Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One. 7:e407172012. View Article : Google Scholar : PubMed/NCBI
36	Xu H, Choi SM, An CS, Min YD, Kim KC, Kim KJ and Choi CH: Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines. Biochem Biophys Res Commun. 328:618–622. 2005. View Article : Google Scholar : PubMed/NCBI
37	Yang H, Zou W, Li Y, Chen B and Xin X: Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biol Ther. 6:942–947. 2007. View Article : Google Scholar : PubMed/NCBI
38	Yang LY, Trujillo JM, Siciliano MJ, Kido Y, Siddik ZH and Su YZ: Distinct P-glycoprotein expression in two subclones simultaneously selected from a human colon carcinoma cell line by cis-diamminedichloroplatinum (II). Int J Cancer. 53:478–485. 1993. View Article : Google Scholar : PubMed/NCBI
39	Yang X and Pagé M: P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin. Oncol Res. 7:619–624. 1995.PubMed/NCBI
40	Comerford KM, Cummins EP and Taylor CT: c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1alpha-dependent P-glycoprotein expression in hypoxia. Cancer Res. 64:9057–9061. 2004. View Article : Google Scholar : PubMed/NCBI
41	Liu M, Li D, Aneja R, Joshi HC, Xie S, Zhang C and Zhou J: PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem. 282:17581–17586. 2007. View Article : Google Scholar : PubMed/NCBI
42	Fitzgerald JB, Schoeberl B, Nielsen UB and Sorger PK: Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2:458–466. 2006. View Article : Google Scholar : PubMed/NCBI
43	Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G and Yaffe MB: Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 149:780–794. 2012. View Article : Google Scholar : PubMed/NCBI
44	Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, Shah NJ, Yaffe MB and Hammond PT: A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal. 7:ra442014. View Article : Google Scholar : PubMed/NCBI